Kamada Ltd. — Report Publication Announcement 2016

Nov 7, 2016

_________ false

����� ��"�	2 380
KAMADA LTD
Corporation no: 511524605	10991
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	07/11/2016
	www.isa.gov.il			www.tase.co.il				Reference:	2016-02-073545	Time of broadcast: 13:59 10:08:52

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment
2016_11_07_KMDA_FDA_Accepts_BLA_for_IgG_FINAL_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: -1	Date of revision of form structure: 31/10/2016
Address: Sapir 7 P.O.B 4081 , Ness-Ziona 74036   ISRAEL , Tel: 08-9406472 , Fax: 08-9406473
E-mail address: liatc@kamada.com   Company site: www.kamada.com
Previous names of reporting entity:
Name of the Signatory: Fhima Lior Position of Signatory in the reporting corporation: Director of Finance Name of Employer Company:
Address: Sapir 7 , Ness Ziona 7403630 Telephone: 08-9913168 Facsimile: 08-9912083 E-mail: liorf@kamada.com 2